Influenza virus-IN-6
Influenza virus-IN-6 (Compound 35) is a potent influenza N-terminal domain of the polymerase acidic protein subunit (PAN) endonuclease inhibitor with an IC50 of 0.20 μM.
For research use only. We do not sell to patients.
- CAS No.: 2919303-26-5
- Formula: C27H26ClNO7
- Molecular Weight:511.95
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDCK | CC50 |
99.52 μM
Compound: 35
|
Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
Cytotoxicity against MDCK cells incubated for 48 hrs by MTT assay
|
[PMID: 36521178] |
Influenza virus-IN-6 (Compound 35) (48 h) shows anti-influenza virus activity in MDCK cells with EC50s of 1.28 ± 0.35, 1.12 ± 0.65, 0.76 ± 0.11 and 0.43 ± 0.06 μM against H1N1, H5N1, H3N2 and Flu B, respectively[1].
Influenza virus-IN-6 (5-20 μM; 24 h) affects virus replication but not virus particles, cells, and adsorption[1].
Influenza virus-IN-6 (2.5-10 μM; 24 h) inhibits influenza viral polymerase activity[1].
Influenza virus-IN-6 displayed promising stability in mouse plasma, liver microsomes, and intestinal S9-UDPGA[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDCK cells
-
Concentration:5, 10 and 20 μM
-
Incubation Time:24 h
-
Result:Decreased nucleoprotein (NP) and matrix protein 2 (M2).
-
Cell Line:MDCK cells
-
Concentration:2.5, 5, 10 and 20 μM
-
Incubation Time:24 h
-
Result:Decreased the expression of viral NP mRNA in a well-defined dose-dependent manner. Inhibited cRNA synthesis in a dose-dependent fashion.
Pharmacokinetic (PK) Profile In Vivo of Influenza virus-IN-6 (Compound 35) after a Single Dose in Rats In Vivo (n = 5)a[1]
| parameter | IV (2 mg/kg) | PO (10 mg/kg) | IP (15 mg/kg) |
| T1/2 (h) | 0.33 ± 0.07 | 0.82 ± 0.16 | 1.07 ± 0.25 |
| Tmax (h) | NA | 0.52 | 0.45 |
| Cmax (ng/mL) | 1586.55 ± 366.48 | 92.20 ± 36.25 | 889.52 ± 233.17 |
| AUC0-t (h·ng/mL) | 536.45 ± 58.72 | 164.30 ± 26.37 | 790.62 ± 188.31 |
| CL (mL/min/kg) | 53.76 ± 13.18 | NA | NA |
| F % | NA | 6.13% | 29.50% |
aIV represents intravenous injection, IP represents intraperitoneal injection, and PO represents the gastrointestinal route. T1/2 is the half-life of the compound exposure in plasma. Tmax is the time taken to reach the maximum concentration. Cmax represents the highest observed concentration. AUC (0–t) is the area under the curve. CL (mL/min/kg) is the clearance. F % is the percent bioavailability.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/C mice, H1N1 infection model[1]
-
Dosage:0, 7.5, 15, and 30 mg/kg/d
-
Administration:Intraperitoneal injection, twice per day for 7 days
-
Result:Exhibited excellent anti-IAV activity in vivo at a dose of 30 mg/kg/d. Still showed potent antiviral activity in vivo, with a survival ratio of approximately 60% against lethal virus infection in mice at 15 mg/kg/d.
-
Animal Model:SD rats[1]
-
Dosage:2, 10 or 15 mg/kg
-
Administration:IV, IP, or PO (Pharmacokinetic Analysis)
-
Result:Showed good pharmacokinetic profiles.
Chemical Information
-
CAS No. 2919303-26-5
-
Molecular Weight 511.95
-
Formula C27H26ClNO7
-
SMILES
CCCOC([C@@H]1CC2=CC(O)=C(C=C2[C@@H](N1C(C3=CC=CC=C3Cl)=O)CC4=CC=C(C(O)=C4)O)O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Influenza virus-IN-6 Related Classifications
HY-152078 Related Classifications
Powered by Bioz